Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) sees a 40% upside from earnings revisions and a strong neuro‑oncology pipeline, but faces regulatory and reimbursement risks that investors must monitor.

Neurocrine Biosciences’ $2.9 billion acquisition of Soleno Therapeutics expands its neuro‑oncology pipeline, adding precision ADCs like SLO‑101 and SLO‑204 with promising early efficacy and a strong regulatory roadmap.

Neurocrine’s $2.9 B acquisition of Soleno adds FDA‑approved VYKAT XR for Prader‑Willi, expanding its rare‑disease portfolio with proven efficacy and a strong safety profile.

Neurocrine’s $2.9 B acquisition of Soleno Therapeutics unlocks Vykat XR’s rare‑disorder revenue, boosting margins and diversifying into a high‑growth, low‑competition market.

Neurocrine Biosciences will host a live investor webinar on March 17, revealing CNS‑forum insights, pipeline progress, and strategic partnerships for neurological & endocrine therapies.

Neurocrine Biosciences reports 29 % Q4 revenue growth driven by Nexvia launch, strong EPS lift, and a strategic roadmap to beat patent cliffs and boost 2026 earnings.

Neurocrine Biosciences shows strong market access and pricing for Piqray®, positioning itself for growth in the $60 billion neuro‑psychiatric sector while navigating patent cliffs and limited pipeline depth.

Neurocrine’s Phase 3 KINECT‑DCP trial of valbenazine for dyskinetic cerebral palsy shows consistent safety but no significant efficacy, highlighting challenges in treating CP-related chorea.

Neurocrine Biosciences’ Phase 3 valbenazine trial for dyskinetic cerebral palsy failed to meet its primary endpoint, revealing key lessons for rare‑disease drug development and investor strategy.

Neurocrine Biosciences will present at the Canaccord Genuity 45th Annual Growth Conference, where its recent stock performance and financial metrics will be discussed.